Compound ID | 1841
Class: Aminoglycoside
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive (incl. Mycobacterium tuberculosis) and Gram-negative bacteria, especially Pseudomonas aeruginosa |
| Description: | Semisynthetic, derived from kanamycin. Veterinary use, human use as parenterial and inhaled formulation (for Mycobacterium avium complex lung disease) |
| Year first mentioned: | 1976 |
| Highest development stage: | Approved by FDA in 1981 |
| Development status: | Approved, off-patent (available in many different formulations, including topical and inhalation) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/37768 |
| Guide to Pharmacology: | amikacin |
| Citations: |
|